transarterial radioembolization + CAPECITABINE + Temozolomide for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Apr 2020: Trial registered, NCT04339036
  2. 7 Oct 2021: Trial started, NCT04339036

The trials

NCT04339036: CapTemY90 for Grade 2/3 NET Liver Metastases

State
Under way
Phase
Phase 2
People
70 planned
Started
7 Oct 2021
Primary completion
1 Jul 2028
Arms
Oral CapTem + Y90 Radioembolization
Results
None posted
  1. 8 Apr 2020: Trial registered
  2. 7 Oct 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.